PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

This study is testing whether an inhaled form of cromolyn sodium (called PHENOGENE-1A) can slow the progression of ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease). The drug works by targeting immune cells called mast cells that may contribute to nerve damage in ALS. **You may be eligible if...** - You are between 18 and 75 years old and have a confirmed diagnosis of ALS - Your symptoms of muscle weakness started within the past 24 months - Your ALS is not too advanced (functional score of 38 or above, breathing capacity above 70%) - You are currently on a stable dose of riluzole (standard ALS medication) - You do not require any breathing assistance **You may NOT be eligible if...** - Your ALS primarily affects your speech or swallowing (bulbar onset) - You require any form of breathing support (CPAP, BiPAP, oxygen) - You have a significant heart condition (e.g., QT prolongation, severe heart failure) - You have moderate to severe lung, liver, or kidney disease - You are very underweight (BMI below 17.5) or over 35 BMI - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.